CD19 and B-cell chronic lymphocytic leukemia: Encouraging data from the TRANSCEND CLL 004 trial[9] using the CD19 CAR T-cell product, lisocabtagene maraleucel (liso-cel), has resulted in the first Food and Drug Administration (FDA) approval for CAR T-cell therapy in CLL.